Drug Profile
PF 4856884
Alternative Names: CovX 060; CVX-060; PF-04856884; PF-4856884Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator CovX
- Developer Pfizer
- Class Antineoplastics; Peptides
- Mechanism of Action Angiopoietin-2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Renal cancer; Solid tumours
Most Recent Events
- 09 May 2013 Discontinued - Phase-I/II for Solid tumours in USA (IV)
- 09 May 2013 Discontinued - Phase-II for Renal cancer in USA (IV)
- 06 Nov 2012 Pfizer terminates Phase-II trial in Renal cancer (combination therapy) in USA (NCT01441414)